Menu Investors Shareholder information FAQs FAQs General FAQs: Who are your Registrars/Depositary Bank and how/why should I contact them? Where can I find information about share prices? Registrar Contact Details: Equiniti Limited: Equiniti Aspect House Spencer Road Lancing West Sussex BN99 6DA Website: www.shareview.co.uk (from here you may email your query securely) Tel: (Within the UK) 0371 384 2991 (Outside the UK) +44 121 415 7067 Lines open 8.30am to 5.30pm (UK time), Monday to Friday (excluding public holidays in England and Wales) J.P. Morgan Chase Bank Registrar: EQ Shareowner Services PO Box 64504 St. Paul MN 55164-0504 Overnight correspondence should be sent to: EQ Shareowner Services 1110 Centre Point Curve Suite 101 Mendota Heights MN 55120-4100 Website: www.shareowneronline.com Tel: +1 877 353 1154 (US toll free) Tel: +1 651 453 2128 (outside the USA) Email anytime at www.shareowneronline.com by selecting Contact Us Ordinary Shareholders FAQs: Please note that the answers that refer to our Registrar, Equiniti, are only relevant to those shareholders who hold GSK shares directly on the Ordinary Register with Equiniti, or through GSK’s Corporate Sponsored Nominee service. If you hold your shares via your broker or through a nominee service, please contact the bank or stockbroker with whom you hold the shares to obtain guidance. ADR Holders FAQs: Dividend FAQs: Please note that the answers that refer to our Registrar, Equiniti, are only relevant to those shareholders who hold GSK shares directly on the Ordinary Register with Equiniti, or through GSK’s Corporate Sponsored Nominee service. If you hold your shares via your broker or through a nominee service, please contact the bank or stockbroker with whom you hold the shares to obtain guidance. Mandated Direct Credit FAQs: Cautionary statements regarding forward-looking statements GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Such factors include, but are not limited to, those described under Item 3.D Principal risks and uncertainties in the company's Annual Report on Form 20-F for 2018. This document was last updated on 13 May 2019. For further questions please contact Equiniti or JP Morgan Chase Bank using the contact details above. You can also contact GSK Investor Relations Team on +44 (0)20 8047 5000 or at GSK.Investor-Relations@gsk.com. RSS Other GSK websites Market website selector GSKPro for healthcare professionals GSK Study Register Quick links COVID-19 response Behind the science About us Products Careers Investors Media Research and development Responsibility Accessibility/legal Accessibility Terms of use Cookie policy Privacy notice Modern Slavery Act statement 2020 PDF - 191.4KB Sitemap Contact us Contact us Partnerships Report a possible side effect Business to business Supplier website Business to business This is our global website, intended for visitors seeking information on GSK’s worldwide business. Our market sites can be reached by visiting our market selector. © 2001-2021 GlaxoSmithKline plc. All rights reserved. Trade marks are owned by or licensed to the GSK group of companies. GlaxoSmithKline plc. Registered in England and Wales No. 3888792. Registered office: 980 Great West Road, Brentford, Middlesex, TW8 9GS, United Kingdom. We use cookies GSK values your privacy and your trust is important to us. We use cookies to enhance your website experience. Some cookies are necessary to run the website. Others are optional: performance cookies show us how you use our website and features; functional cookies remember your preferences; and advertising cookies help us share relevant content.Cookie Policy Show detail ❮ OPT OUT ACCEPT ALL